Wasatch Advisors LP Boosts Holdings in Mesa Laboratories, Inc. $MLAB

Wasatch Advisors LP raised its position in Mesa Laboratories, Inc. (NASDAQ:MLAB) by 125.8% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 115,668 shares of the medical instruments supplier’s stock after purchasing an additional 64,435 shares during the period. Wasatch Advisors LP’s holdings in Mesa Laboratories were worth $11,515,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in MLAB. Northwestern Mutual Wealth Management Co. raised its position in shares of Mesa Laboratories by 5,366.7% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 328 shares of the medical instruments supplier’s stock worth $26,000 after buying an additional 322 shares in the last quarter. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Mesa Laboratories in the 4th quarter valued at about $27,000. Kestra Advisory Services LLC purchased a new stake in shares of Mesa Laboratories in the 4th quarter valued at about $55,000. BNP Paribas Financial Markets boosted its position in shares of Mesa Laboratories by 30.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 1,029 shares of the medical instruments supplier’s stock valued at $69,000 after acquiring an additional 243 shares during the last quarter. Finally, Tower Research Capital LLC TRC boosted its position in shares of Mesa Laboratories by 432.9% during the 2nd quarter. Tower Research Capital LLC TRC now owns 842 shares of the medical instruments supplier’s stock valued at $79,000 after acquiring an additional 684 shares during the last quarter. Institutional investors own 90.60% of the company’s stock.

Mesa Laboratories Stock Performance

NASDAQ MLAB opened at $112.80 on Thursday. Mesa Laboratories, Inc. has a 52-week low of $58.83 and a 52-week high of $113.99. The company has a fifty day moving average of $100.51 and a 200-day moving average of $95.69. The company has a market capitalization of $631.68 million, a P/E ratio of 134.29 and a beta of 0.92. The company has a debt-to-equity ratio of 0.78, a quick ratio of 1.29 and a current ratio of 1.72.

Mesa Laboratories (NASDAQ:MLAB) last released its quarterly earnings results on Monday, August 10th. The medical instruments supplier reported $2.68 earnings per share for the quarter. Mesa Laboratories had a return on equity of 22.87% and a net margin of 1.92%.The business had revenue of $60.14 million for the quarter.

Mesa Laboratories Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 15th. Investors of record on Monday, August 31st will be issued a dividend of $0.16 per share. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend is Monday, August 31st. Mesa Laboratories’s dividend payout ratio (DPR) is currently 53.33%.

Insider Buying and Selling

In other Mesa Laboratories news, SVP Brian David Archbold sold 2,516 shares of the company’s stock in a transaction that occurred on Monday, June 22nd. The stock was sold at an average price of $89.50, for a total value of $225,182.00. Following the completion of the sale, the senior vice president owned 6,377 shares of the company’s stock, valued at $570,741.50. This represents a 28.29% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CAO Lyndsey Elizabeth Crennen sold 442 shares of the company’s stock in a transaction that occurred on Monday, June 22nd. The stock was sold at an average price of $89.50, for a total value of $39,559.00. Following the completion of the sale, the chief accounting officer directly owned 2,020 shares of the company’s stock, valued at approximately $180,790. This represents a 17.95% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 8,277 shares of company stock worth $770,122 in the last quarter. 2.80% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings upgraded shares of Mesa Laboratories from a “sell (d)” rating to a “hold (c-)” rating in a research report on Tuesday. Three equities research analysts have rated the stock with a Hold rating, According to MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $94.00.

Mesa Laboratories Profile

Mesa Laboratories, Inc (NASDAQ: MLAB) is a global provider of instrumentation products designed for critical process monitoring, testing and calibration. Headquartered in Lakewood, Colorado, the company serves a diverse set of end markets including healthcare, pharmaceutical, food and beverage, energy and industrial sectors. With a focus on precision measurement and validation, Mesa Laboratories helps customers ensure regulatory compliance, product safety and operational efficiency across complex manufacturing and sterilization processes.

The company’s product portfolio encompasses biological and chemical indicators for sterilization process validation, digital data loggers and sensors for environmental monitoring, and optical gas analyzers with sample-conditioning solutions for oil, gas and petrochemical applications.